Intrum UK agrees deal to acquire Capquest and Mars UK platforms from Arrow Global

Credit management services company Intrum has agreed a £36.5m deal to buy the Capquest and Mars UK servicing platforms from European fund manager Arrow Global, along with a £121.25m investment for 50% of Arrow’s UK back book consumer portfolios.

The purchase includes outsourcing contracts with major financial institutions as well as the continued servicing of the Arrow UK consumer back book portfolios. It marks a significant stage in Intrum’s UK growth plans, following the company’s expansion in third party servicing over the recent years.

Intrum’s acquisition of Capquest and Mars UK will include approximately 800 roles, as well as two Glasgow servicing centres and premises in Manchester. The deal is subject to approval by the Financial Conduct Authority and is expected to take six months to complete.

“The agreement we have reached with Arrow Global further cements our commitment to third party servicing in the UK and underlines our growth ambitions in this market,” said Intrum Managing Director for the UK and Ireland Eddie Nott. “We believe the combined group presents a stronger proposition to prospective clients and our existing partners.”

Nott added that the cultures of the two businesses are highly compatible, and the combined team will grow the business together. “We help our clients prosper by caring for their customers. This customer-centric approach, combined with Intrum’s scale, track record and sector expertise, means we are ideally placed to acquire the Capquest and Mars UK platforms.”

The acquisition accelerates Intrum’s long-standing UK growth plans. “The purchase aligns with our investment approach and is formed of key asset classes for Intrum UK, including several significant long-term contracts. This will lead to exciting opportunities for our existing and new teams and we look forward to welcoming those joining us,” said Nott.

The acquisition is expected to complete in the second quarter of 2023, subject to regulatory approvals.